

Mipasetamab uzoptirine

Cat. No.:	HY-P99734
CAS No.:	2304799-73-1
Target:	TAM Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers ^[1] .								
In Vitro	<p>Mipasetamab uzoptirine binds to both soluble and membranous AXL, and is rapidly internalized by AXL-expressing tumor cells, allowing release of PBD dimer, DNA interstrand cross-linking, and subsequent cell killing^[1].</p> <p>Mipasetamab uzoptirine selectively inhibits growth of AXL-positive human cancer cell lines (Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C)^[1].</p> <p>Mipasetamab uzoptirine (0 h, at 4°C) shows strong cell surface binding in SN12C cells, and colocalize well with lysosome at 1 h^[1].</p> <p>Mipasetamab uzoptirine increases DNA interstrand cross-links levels in SN12C cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C</td> </tr> <tr> <td>Concentration:</td> <td>0-20 nM approximately</td> </tr> <tr> <td>Incubation Time:</td> <td>5-8 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell growth with IC50s of 0.47, 0.59, 0.02, 0.35, 0.11, 2.2, 0.83, 9.29, 14.62 nM respectively.</td> </tr> </table>	Cell Line:	Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C	Concentration:	0-20 nM approximately	Incubation Time:	5-8 days	Result:	Inhibited cell growth with IC50s of 0.47, 0.59, 0.02, 0.35, 0.11, 2.2, 0.83, 9.29, 14.62 nM respectively.
Cell Line:	Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C								
Concentration:	0-20 nM approximately								
Incubation Time:	5-8 days								
Result:	Inhibited cell growth with IC50s of 0.47, 0.59, 0.02, 0.35, 0.11, 2.2, 0.83, 9.29, 14.62 nM respectively.								
In Vivo	<p>Mipasetamab uzoptirine (0.3-1 mg/kg, i.v.) inhibits tumor growth in MDA-MB-231 TNBC xenograft and SN12C xenograft mice model^[1].</p> <p>Mipasetamab uzoptirine (6 mg/kg, i.v.) is well tolerated and shows excellent stability in rats^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>SN12C xenograft mice model^[1].</td> </tr> <tr> <td>Dosage:</td> <td>0.3-1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v.</td> </tr> </table>	Animal Model:	SN12C xenograft mice model ^[1] .	Dosage:	0.3-1 mg/kg	Administration:	i.v.		
Animal Model:	SN12C xenograft mice model ^[1] .								
Dosage:	0.3-1 mg/kg								
Administration:	i.v.								

Result:	Inhibited tumor growth and increased survival rate.
---------	---

REFERENCES

[1]. Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA